FDA’s drug eval­u­a­tion wing launch­es new AI over­sight pan­el

The FDA is hop­ing that rapid­ly-ad­vanc­ing ar­ti­fi­cial in­tel­li­gence ca­pa­bil­i­ties will not pass it by.

The agency’s Cen­ter for Drug Eval­u­a­tion and Re­search (CDER) has launched …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER